Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

Anavex rapidly advances ANAVEX 2-73 for Alzheimer's disease, Phase I clinical trial progressing well
Sources News Release

http://www.sources.com/Releases/NR1357.htm

Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written:  06/07/2011
Year Published:  2011  
Resource Type:  Article

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose

Abstract:  Hoboken, NJ – July 6, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose steps and follows the successful completion of the 1 mg and 10 mg dosing rounds. There have been no adverse effects recorded after the administration of ANAVEX 2-73 at the doses studied to date.

Trial participants are ...
To read the full release go to http://www.sources.com/Releases/NR1357.htm

Topics


Sources-journalists use the sources website to find you


AlterLinks
c/o Sources


© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.